49 results about "Monoacylglycerol lipase" patented technology

This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating cancer or inhibiting tumor growth by targeting MAGL with MAGL specific inhibitors. The invention further provides methods of screening for MAGL inhibitors with improved biochemical and pharmaceutical properties.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:

wherein Y, Z, R¹, and s are defined herein.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows:

wherein Y, Z, and n are defined herein; and

wherein Y_b and Z_b are as defined herein.

The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I):

wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:

wherein Y, Z, R¹, and s are defined herein.

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows:

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:

wherein Y, Z, R¹, and s are defined herein.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:

wherein Y, Z, R¹, and s are defined herein.

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows:

wherein R¹, W and

are defined herein.

Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: Formula (I), wherein Y, Z, and R are defined herein.

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows:

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

The present invention is in the field of oil processing, and specifically the present invention relates to a process of hydrolyzing oil with a high melting point, such as hydrogenated castor oil (HCO), by lipase. In an embodiment of the invention, there is provided a process of hydrolyzing oil having a higher melting point to obtain a hydrolysis product, the process comprising: a step of mixing water, an organic solvent, and a lipase with the oil to form a mixture, and a step of hydrolyzing the oil in the mixture, wherein the lipase comprises one or more lipase derived from Thermomyces sp. butnot any monoacylglycerol lipase or any lipase derived from Rhizomucor sp., and the organic solvent is any one selected from a sterically hindered alcohol, a non-polar organic solvent, and a mixture of a water-miscible organic solvent with a non-polar organic solvent.

The invention relates to the field of pharmaceutical chemistry, specifically to medical application of tanshinone IIA derivatives (I) and (II). Pharmacological experiments show that the compound has strong monoacylglycerol lipase inhibitory activity and good analgesic activity. The compound is expected to be used for developing a novel analgesic drug based on the clinic use of a monoacylglycerol lipase inhibitor.